Literature DB >> 15367641

Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection.

Angela Ciuffi1, Gabriela Bleiber, Miguel Muñoz, Raquel Martinez, Corinne Loeuillet, Manuela Rehr, Marek Fischer, Huldrych F Günthard, Annette Oxenius, Pascal Meylan, Sebastian Bonhoeffer, Didier Trono, Amalio Telenti.   

Abstract

Isolated primary human cells from different donors vary in their permissiveness-the ability of cells to be infected and sustain the replication of human immunodeficiency virus type 1 (HIV-1). We used replicating HIV-1 and single-cycle lentivirus vectors in a population approach to identify polymorphic steps during viral replication. We found that phytohemagglutinin-stimulated CD4(+) CD45RO(+) CD57(-) T cells from healthy blood donors (n = 128) exhibited a 5.2-log-unit range in virus production. For 20 selected donors representing the spectrum of CD4 T-cell permissiveness, we could attribute up to 42% of the total variance in virus production to entry factors and 48% to postentry steps. Efficacy at key intracellular steps of the replicative cycle (reverse transcription, integration, transcription and splicing, translation, and budding and release) varied from 0.71 to 1.45 log units among donors. However, interindividual differences in transcription efficiency alone accounted for 64 to 83% of the total variance in virus production that was attributable to postentry factors. While vesicular stomatitis virus G protein-mediated fusion was more efficacious than CCR5/CD4 entry, the latter resulted in greater transcriptional activity per proviral copy. The phenotype of provirus transcription was stable over time, indicating that it represents a genetic trait.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367641      PMCID: PMC516423          DOI: 10.1128/JVI.78.19.10747-10754.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Hide, shield and strike back: how HIV-infected cells avoid immune eradication.

Authors:  B Matija Peterlin; Didier Trono
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

2.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 3.  Death by deamination: a novel host restriction system for HIV-1.

Authors:  Stephen P Goff
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

4.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

5.  Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells.

Authors:  Youichi Suzuki; Naoko Misawa; Chihiro Sato; Hirotaka Ebina; Takao Masuda; Naoki Yamamoto; Yoshio Koyanagi
Journal:  Virus Genes       Date:  2003-10       Impact factor: 2.332

6.  T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Authors:  Jason M Brenchley; Brenna J Hill; David R Ambrozak; David A Price; Francisco J Guenaga; Joseph P Casazza; Janaki Kuruppu; Javaidia Yazdani; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus.

Authors:  Audrey Brussel; Pierre Sonigo
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

Authors:  Christophe Butticaz; Angela Ciuffi; Miguel Muñoz; Jérôme Thomas; Alan Bridge; Stephanie Pebernard; Richard Iggo; Pascal Meylan; Amalio Telenti
Journal:  Antivir Ther       Date:  2003-10

9.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

View more
  23 in total

1.  Characterization of the influence of mediator complex in HIV-1 transcription.

Authors:  Alba Ruiz; Eduardo Pauls; Roger Badia; Eva Riveira-Muñoz; Bonaventura Clotet; Ester Ballana; José A Esté
Journal:  J Biol Chem       Date:  2014-08-06       Impact factor: 5.157

2.  Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.

Authors:  Gabriela Bleiber; Margaret May; Raquel Martinez; Pascal Meylan; Jürg Ott; Jacques S Beckmann; Amalio Telenti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 3.  Genomics meets HIV-1.

Authors:  Amalio Telenti; David B Goldstein
Journal:  Nat Rev Microbiol       Date:  2006-10-09       Impact factor: 60.633

4.  A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers.

Authors:  Jin Leng; Hsin-Pin Ho; Maria J Buzon; Florencia Pereyra; Bruce D Walker; Xu G Yu; Emmanuel J Chang; Mathias Lichterfeld
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

5.  In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells.

Authors:  Johannes Nemeth; Valentina Vongrad; Karin J Metzner; Victoria P Strouvelle; Rainer Weber; Patrick Pedrioli; Ruedi Aebersold; Huldrych F Günthard; Ben C Collins
Journal:  Mol Cell Proteomics       Date:  2017-02-21       Impact factor: 5.911

6.  Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Authors:  Ingrid Karlsson; Jean-Charles Grivel; Silvia Sihui Chen; Anders Karlsson; Jan Albert; Eva Maria Fenyö; Leonid B Margolis
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Variability in a dominant block to SIV early reverse transcription in rhesus monkey cells predicts in vivo viral replication and time to death.

Authors:  Thomas F Rogers; So-Yon Lim; T J Sundsvold; Tiffany Chan; Ariel Hsu; Norman L Letvin
Journal:  Virol J       Date:  2010-04-26       Impact factor: 4.099

8.  Intracellular dynamics of HIV infection.

Authors:  Janka Petravic; Paula Ellenberg; Ming-Liang Chan; Geza Paukovics; Redmond P Smyth; Johnson Mak; Miles P Davenport
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

9.  WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.

Authors:  R Alvarez; J Reading; D F L King; M Hayes; P Easterbrook; F Farzaneh; S Ressler; F Yang; D Rowley; A Vyakarnam
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells.

Authors:  Maria J Buzon; Yue Yang; Zhengyu Ouyang; Hong Sun; Katherine Seiss; Jerome Rogich; Sylvie Le Gall; Florencia Pereyra; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.